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Aims: The purpose of the study was to assess quality of life, socioeconomic parameters,
and costs of conventional therapy in patients treated by catheter ablation for atrial
fibrillation (AF).
Methods: The study included 160 patients treated by catheter ablation for AF who fulfilled a
minimum of 2-year follow-up. Quality of life using EQ-5D questionnaire, and days of
hospitalization and working incapacity were evaluated before ablation and every 6 months
after ablation. Further, one-year costs of conventional therapy for AF were assessed before
and after ablation.
Results: Quality of life was significantly improved at each post-ablation stage. EQ-5D index
increased from baseline 68714 to 76717 after 2 years (po0.001), and EQ-VAS score from
baseline 65717 to 71715 after 2 years (p¼0.01). Significant reduction was further observed
in the count of hospitalization days and days of working incapacity (both po0.01). The cost
of conventional therapy per patient per year decreased from 49,337 Czech Crowns (1974h)
before ablation to 16.504 (660h) and 13.576 CZC (543h) in the first and second post-ablation
year, respectively.
Conclusion: AF ablation was associated with significant improvement in quality of life, and
decrease in days of hospitalization and working incapacity. There was more than three-fold
reduction in the costs of conventional therapy observed in the first two years after ablation.
& 2012 Published by Elsevier Urban & Partner Sp.z o.o. on behalf of The Czech Society of
Cardiology.
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Quality of life (QoL) and costs of medical and social care
represent, in addition to mortality, the fundamental criteriaed by Elsevier Urban & P
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Table 1 – Baseline characteristics.
Females 41 (26%)
Age (years) 58710
Working 93 (58%)
Retired 13 (8%)
Invalids 54 (34%)
Body mass index 28,874,3
AF duration (months) 57752
AF paroxysmal 89 (56%)
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 4 2 1 – e 4 2 7e422been steadily growing [1,2]. In addition to the increasing
direct medical costs spent on treatment of AF and its
complications, expenses on working incapacity, lost profits,
invalidity, and social benefits also need to be taken into
consideration.
This study sought to evaluate quality of life and socio-
economic parameters in patients undergoing AF ablation. It
further assessed costs of conventional therapy one year
before ablation and two years after ablation.
AF persistent 15 (9%)
FS long-standing persistent 56 (35%)
SBP baseline (mmHg) 132718
DBP baseline (mmHg) 83711
HR baseline (bpm) 81720
Hypertension 81 (51%)
Diabetes mellitus 20 (13%)
Hyperthyreoidism 11 (7%)
Hypothyreoidism 16 (10%)
Stroke/TIA 13 (8%)
Dilated cardiomyopathy 13 (8%)
History of myocarditis 3 (2%)
History of pericarditis 1 (0,6%)
Mitral valve disease 14 (9%)
CAD 13 (8%)
History of heart surgery 5 (3%)
History of PCI 4 (2%)
Bronchopulmonary disease 11 (7%)
Pacemaker 3 (2%)
CAD¼coronary artery disease; HR¼heart rate; PCI¼percutaneous
catheter intervention; SBP, DBP¼systolic and diastolic blood pres-
sure; TIA¼transitory ischemic attack.2. Methods
2.1. Patients
The study included 160 consecutive patients aged Z18 years
who underwent their first catheter ablation for symptomatic
AF in the year 2007 in two centers, and who were subse-
quently prospectively followed-up for 2 years.
2.2. Data collection
Demographic, medical, social, and socioeconomic data
obtained from the patients’ history and examinations during
the index hospitalization and subsequent outpatient visits
were analyzed. This data was recorded into a questionnaire
and stored on an internet portal under the personal
patient’s code.
2.3. Assessment of quality of life and socioeconomic
parameters
QoL was assessed by the European Quality of Life Group
instrument—EQ-5D self report questionnaire. This standar-
dized questionnaire consists of 2 parts—EQ-VAS (visual
analog scale of 0–100 for recording individuals’ rating of their
current health-related QoL state), and the 3-level, 5-
dimensional descriptive system (EQ-5D), which evaluates
mobility, self-care, usual activities, pain/discomfort and anxi-
ety/depression on a 0–100 scale using the European value set
[3]. Patients filled out the questionnaire on their own without
any assistance from medical staff before, and every six
months after the ablation, when the questionnaires were
sent them home by post. Counts of days of hospitalization
and working capacity per patient per 6 month were assessed
before ablation and for each 6-month post-ablation period.
All patients completed 24-month follow-up.
2.4. Assessment of costs of conventional therapy
Yearly costs of conventional therapy per patient one year
before ablation and two years after ablation were evaluated.
At the same time, costs of ablation therapy were ascertained.
Repeat ablation was performed by the end of the follow-up
period in 57 (36%) patients; 7 (4%) patients underwent two
repeat ablation procedures. Thus, in total, 64 repeat ablation
procedures were calculated.
The count of outpatient visits was averaged for each follow-
up period. The expenses on days spent in working incapacity
were calculated from mean salary in the Czech Republicwhich was 22.748 Czech Crowns (CZC) (910h). The costs of
hospitalizations were calculated from the daily rate applied
by Czech General Health Insurance Company. Costs of drugs
were obtained from their mean price, costs of laboratory and
diagnostic tests were determined from the price list of the
Czech General Health Insurance Company. The costs of
diagnostic/therapeutic procedures were calculated from the
count of procedures per 1 patient per 1 year in relation to the
point rating of a particular procedure. The remaining health
care costs were calculated from the current rating of the
Czech General Health Insurance Company.
2.5. Statistical analysis
Data from the questionnaires was edited in the Microsoft
Excel verze 9.0.2812 program. All analyses were performed
using the Statistica version 6.1 software (Statsoft, Inc.).
Continuous variables were expressed as mean7standard
deviation and compared by the 2-tailed Student’s t-test. Cate-
gorical variables were expressed as percentages and compared
by w2-test. A p value o0.05 was considered significant.3. Results
3.1. Mortality and questionnaire recoverability
During the follow up, 2 (1%) patients died 12 and 20 months
after ablation, respectively. Hemorrhagic stroke was the cause
of death in both patients who continued to use warfarin.
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(85%), and 122 (76%) patients after 6, 12, 18 and 24 months,
respectively.3.2. Baseline characteristics
Baseline characteristics are listed in Table 1. Palpitations,
sweating, fatigue, and incapacity dominated the symptoms
(Table 2). Baseline medication is shown in Table 3.3.3. Ablation procedure characteristics
Procedure time (304777 min), fluoroscopy time (34731 min),
and radiofrequency application time (89752 min) reflected
participation of operators with different experience and
inclusion of patients with persistent AF requiring more
complex ablation strategy. Occurrence of 3 serious complica-
tions in 3 (2%) patients, namely cardiac tamponade in 2 (1.3%)
patients, and transient ischemic attack in 1 (0.6%) patients
did not differ from the results of worldwide registries [4,5].3.4. Quality of life—questionnaire EQ-5D
EQ-5D index of quality of life improved already after 6
months (p¼0.02), and the improvement persisted at all the
follow-up stages (all po0.001). EQ-VAS score of quality of life
increased significantly after 12 months (p¼0.02), and its
amelioration also persisted after 18 and 24 months, respec-
tively (po0.01, and p¼0.01, respectively) (Fig. 1).Table 2 – Symptoms.
Palpitations 131 (82%)
Sweating 50 (31%)
Fatigue 58 (36%)
Incapacity 100 (62%)
Chest oppression 28 (17%)
Dyspnea 78 (48%)
Presyncope 24 (15%)
Syncope 10 (6%)
Table 3 – Baseline medication.
Propafenone 36 (23%)
Sotalol 20 (13%)
Amiodarone 56 (35%)
Betablocker 78 (48%)
Digoxin 7 (4%)
ACE-I 52 (32%)
ARB 12 (7%)
Diuretics 42 (26%)
ASA 3 (2%)
Statin 32 (20%)
Warfarin 154 (96%)
ACE-I¼angiotensin converting enzyme blocker; ARB¼angiotensin
II receptor blocker; ASA¼acetylsalicylic acid.3.5. Socioeconomic parameters
Pre-ablation count of hospitalization days/1 patient/6 months
was 4.2 days, and decreased to 1.3 days 6 months after
ablation (p¼0.01), and to 1.1, 1.0, and 0.9 days, respectively
after 12, 18, and 24 months, respectively (all po0.01) (Fig. 2).
Pre-ablation count to days of working incapacity/1 patient/
6 months amounted to 14.2, and decreased insignificantly
after 6 months to 12.5 days, however, subsequently dropped
significantly to 4.9 days after 12 months (p¼0.02), and to 2.0
and 1.7 days, respectively, after 18 and 24 months (both
po0.01) (Fig. 2).
3.6. Costs of conventional therapy
The mean cost of ablation procedures per 1 patient including
repeat ablations was 259.000 CZC (10.360h). The costs of
conventional therapy per 1 patient per 1 year summed up
to 49.337 CZC (1.974h) before ablation, while they were
reduced to 16.504 CZC (660h) in the first post-ablation year
and to 13.576 CZC (543h) in the second post-ablation year
(Table 4)4. Discussion
This study analyzed quality of life, socioeconomic para-
meters, and costs conventional therapy in patients under-
going catheter ablation for AF. The main findings of the study
are as follows: (1) quality of life assessed by the questionnaire
EQ-5D improved significantly in both its portions at all
follow-up stages; (2) ablation was associated with significant
decrease in hospitalization days and days of working inca-
pacity; (3) more than three-fold reduction in the cost of
conventional therapy was observed in the first two years
after ablation.
4.1. Quality of life and socioeconomic parameters
This study corroborated prior observations of significant
improvement of QoL in patients after catheter ablation of
AF [6–9]. Recent studies similarly to our study demonstrated
that the improvement of quality of life persisted long term
[10,11]. In addition, the counts of days of hospitalization and
working incapacity were significantly reduced. The greatest
benefit was achieved after one year and later when AF/ atrial
tachycardia recurrences disappeared either spontaneously (in
case of early temporary arrhythmia), or after successful
repeat ablation. Specifically, decrease in days of working
incapacity was only insignificant after 6 months, while a
7–8 fold reduction was observed after 18 and 24 months.
4.2. Cost of conventional therapy
Earlier analysis in patients with AF treated by private inter-
nists/cardiologists in the Czech Republic and not undergoing
catheter ablation demonstrated 1-year costs of conventional
AF therapy per 1 patient to amount to 42.407 CZC (1.697h) [12].
The Czech costs of conventional AF therapy were approxi-
mately half the common costs in western European countries
Fig. 1 – Panels A and B show evolution of EQ-5D index and EQ-VAS score of quality of life on a 0–100 scale before ablation and
at the 6, 12, 18, and 24 month post-ablation stages as assessed by EQ-5D questionnaire. Improvements in both portions
became significant after 6 months and remained significant after 2 years (p-values in the text).
Fig. 2 – Figure shows number of days of hospitalization and
number of days of working incapacity per patient per 6
months before ablation and in the 2-year post-ablation
period. Reductions in the number of days of hospitalization
and working incapacity became significant after 6 and 12
months, respectively (p-values in the text).
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expenses on AF treatment in patients undergoing catheter
ablation were assessed, and by reaching 49.337 CZC (1.974h)per patient per year exceeded the expenses found in the
above mentioned population [12] by nearly 7.000 CZC (280h).
It can be speculated that patients undergoing ablation are
likely to be more symptomatic and require more pharmaco-
logic and other interventions. Considering the costs of all
ablation procedures per 1 patient of 259.000 CZC (10.360h),
and considering the costs of continuing conventional therapy
of 16.504 CZC (660h) in the first post-ablation year and 13.576
CZC (543h) in the second post-ablation year, respectively, and
estimating similar costs of conventional therapy during the
following years, the costs of ablation therapy should be paid
back within 7–8 years.
This simple arithmetic calculation, however, does not reflect
more complex health and social care issues. First, progression
of complications of AF and use of more expensive drugs may
escalate the costs of conventional therapy in patients who do
not undergo timely ablation. Arrhythmia-induced cardiomyo-
pathy, which is reversible after successful ablation [15,16], often
kindles a chain of wrong diagnostic and curative steps (repeat
negative coronary angiographies, primary preventive ICD
implantation, etc.) without hope in cure, however, with
immense subsequent expenses on compromise therapeutic
strategies (heart failure therapy, ICD reimplantations, etc).
Medical treatment with angiotensin-converting enzyme
Table 4 – Cost of conventional therapy for AF.
Cost of 1 item (CZC) N. items/1 pt/1 year Cost/1 pt/1 year
Procedure 1 year pre-
ablation
1st year post-
ablation
2nd year post-
ablation
1 year pre-
ablation
1st year post-
ablation
2nd year post-
ablation
1 year pre-
ablation
1st year post-
ablation
2nd year post-
ablation
Examination by
cardiologist
304 304 304 5.2 5.4 4.6 1581 1642 1.398
AAD and AC 3726 3726 3726 3726 3726 3726
Hospitalization for AF 5481 5481 5481 4.2 1.1 0.91 23,020 6029 4987
N. days of working
incapacity
4549 454.9 4549 14.2 4.9 1.7 6460 2229 772
Electrical
cardioversion
1080 1080 1080 1.4 0.25 0.16 1512 367 173
Stroke therapy 4048 0.08 324
Negative SCA 44,375 0.19 8431
Pacemaker 88,600 0.02 1772
Examination bv
practitioner
725 725 725
Stomatology 829 829 829
Transportation 126 126 126
Rescue service 89 89 89
Health affliction
voucher 410 410 410
Spa, sanatoria 332 332 332
Total/1patient 49,337 16,504 13,567
AAD¼antiarrhythmic drug; AC¼anticoagulation; PM¼pacemaker; pt¼patient; SCA¼selective coronary angiography.
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c o r e t v a s a 5 4 ( 2 0 1 2 ) e 4 2 1 – e 4 2 7e426inhibitors or angiotensin II receptor blockers that have become
routine in AF therapy also represent not a trivial expense. In
addition, for example, considering the cost of an average 5mg
daily warfarin dose of 2.12 CZC (0.08h) a day, and the cost of
dabigatran 150mg bid of 71.7 CZC ( 2,8h ) (note: current price of
100 tablets of warfarin 5mg is 212 CZC (8,5h), and the price of 60
capsules of dabigatran 150mg remains 2.150 CZC (86h) ), the
changeover from warfarin to dabigatran would increase the
cost of 1-year anticoagulation from 774 (31h) to 26.171 CZC
(1.047h). This would project onto yearly rise in costs of conven-
tional therapy from 49.337 (1.974h) to 74.734 CZC (2.990h).
Further e.g., costs of catheter ablation for type I atrial flutter
at the time, when AF already occurred simultaneously and
might have been eliminated by the same ablation procedure,
were not also involved in the analysis.
On the other hand, the first two years after ablation
represent a period of possible repeat ablation procedures
and relatively intensive outpatient care, while full clinical
and economic benefit is achieved only later. Therefore, it is
possible that the costs of continuing conventional therapy in
the subsequent post-ablation years are lower, and AF ablation
becomes cost-effective earlier.
Finally, this study did not calculate savings resulting from
recovered health and working capacity, or, on the contrary,
expenditures on further disease progression, continuing
working incapacity and invalidity. Importantly, AF ablation
immensely impacts an otherwise healthy population of an
average age of 55–60 years. With regard to this issue, this
study group included 8% of invalid patients in whom AF itself
was the dominant cause of invalidity. AF ablation, in stark
contrast to other expensive cardiology disciplines, treats
mainly active and productive patients, in whom the expenses
on ablation will often be paid back still in their productive
age. Absolute values of quality of life indicate that these
patients return into the state of full health and productivity.
Therefore the global economic profit from successful ablation
is possibly achieved much earlier than can be calculated from
direct costs of medical care. More reliable calculation of cost-
efficacy in relation to social expenditures would, however,
need more complex mathematical models [17].4.3. Limitations
Because the follow-up questionnaires were mailed to the
patients home, and because the patients responded volunta-
rily, the data evaluation was limited only to the responders.
However, the questionnaire recovery between 66% and 84% at
different stages of the study was favorable when compared
with similar questionnaire projects. Furthermore, this study
practice ensured independence of the responding patients
who were not influenced of even biased by the medical staff
assistance.5. Conclusions
Catheter ablation of AF significantly improved QoL and reduced
hospital admissions and working incapacity at all stages of the
2-year follow-up. In addition, more than three-fold reduction inthe costs of conventional therapy was achieved in the first two
years after ablation.Acknowledgment
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